RxDoctor Payments Data

Manuel Garcia-Toca, MD

Vascular Surgery · Stanford, CANPI 1437377280

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,588 of the $6,214 with a category attached, or 89.9%. 19 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 31.4% of the total. 2025 is the largest year on record at $2,179, 5.2 times the $422 reported in 2019.

$6,214in general payments, 2019–2025

Across 74 payments — averaging $83.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$2K
  • Bolton Medical Inc$943
  • Shockwave Medical, Inc$844
  • Inari Medical, Inc.$509
  • Medtronic$355
  • Penumbra, Inc.$248
  • plus $1K from 13 others
$77,327in research payments, 2019–2025

Across 51 payments — averaging $1516.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$46K
  • Boston Scientific$24K
  • Humacyte Global, Inc.$8K

What the payments were for

  • Grants$240%
  • Travel & lodging$5359%
  • Food & beverage$5,58890%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,214 in reported general payments places this provider in the 60th percentile of 519 vascular surgery providers in California.

See all vascular surgery providers in California

Medicare billing

Part B allowed, 2024
$45,528
Medicare patients
171
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium12$46

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →